Tumor-educated platelet blood tests for Non-Small Cell Lung Cancer detection and management

We report RNA-seq data of 766 blood platelet samples, including 399 Non-Small Cell Lung Cancer (NSCLC) patients from different stages (I-IV) and 367 asymptomatic individuals (Controls). Our data explains how tumor-educated platelet (TEP)-derived spliced RNA can serve as a biomarker for minimally-invasive clinical blood tests on assisting the detection and management of lung cancer patients. Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing EDTA anti-coagulant by standard centrifugation. Total RNA was extracted from the platelet pellet, subjected to cDNA synthesis and SMARTer amplification, fragmented by Covaris shearing, and prepared for sequencing using the Truseq Nano DNA Sample Preparation Kit. Subsequently, pooled sample libraries were sequenced on the Illumina Hiseq 2500 or 4000 platform. All steps were quality-controlled using Bioanalyzer 2100 with RNA 6000 Picochip, DNA 7500 and DNA High Sensitivity chips measurements. For further downstream analyses, reads were quality-controlled using Trimmomatic, mapped to the humane reference genome using STAR, and intron-spanning reads were summarized using HTseq.